Evidence map›Paper›PMID 35784553›Full record

ArticleFrontiers in endocrinology2022

Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis.

Tongtong Ye, Jingwen Zhang, Di Wu, Junfeng Shi, Zengguang Kuang, Yuting Ma, Qian Xu, Bing Chen, Chengxia Kan, Xiaodong Sun and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Tongtong YeDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Jingwen ZhangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Di WuDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Junfeng ShiDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Zengguang KuangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Yuting MaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Qian XuDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Bing ChenDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Chengxia KanDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Xiaodong SunDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Fang HanDepartment of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Weifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. However, the effects of EMPA on obesity-related kidney disease have not been determined. The heme oxygenase-1 (HO-1)-adiponectin axis is an essential antioxidant system with anti-apoptotic and anti-inflammatory properties. This study explored whether EMPA improves obesity-related kidney disease through regulation of the renal HO-1-mediated adiponectin axis. C57BL/6J mice were assigned to control, high-fat diet (HFD) groups, and EMPA (10 mg/kg) groups. HFD mice showed metabolic abnormality and renal injury, including increased urinary albumin excretion, morphologic changes, and lipid accumulation. EMPA treatment improved metabolic disorders and attenuated lipotoxicity-induced renal injury. Furthermore, EMPA treatment ameliorated renal NLRP3 inflammasome activity and upregulated the HO-1-adiponectin axis. Our findings indicate that EMPA improves obesity-related kidney disease through reduction of NLRP3 inflammasome activity and upregulation of the HO-1-adiponectin axis, suggesting a novel mechanism for SGLT2i-mediated renal protection in obesity.

Indexed as

AdiponectinInflammasomesAnimalsBenzhydryl CompoundsGlucosidesHeme Oxygenase-1KidneyMembrane ProteinsMiceMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 ProteinObesityAdiponectinBenzhydryl CompoundsempagliflozinGlucosidesHeme Oxygenase-1Hmox1 protein, mouseInflammasomesMembrane ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseEmpagliflozinHO-1kidney diseaseNLRP3obesity

Identifiers

PMID35784553
PMCPMC9248377
OpenAlexW4283077549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.